Mei Pan

ORCID: 0009-0004-4277-0609
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Viral Infections and Vectors
  • Cancer Immunotherapy and Biomarkers
  • Vector-Borne Animal Diseases
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Endometrial and Cervical Cancer Treatments
  • Lung Cancer Treatments and Mutations
  • Vector-borne infectious diseases
  • Economic and Financial Impacts of Cancer
  • interferon and immune responses
  • Animal Virus Infections Studies
  • Molecular Biology Techniques and Applications
  • Plant Virus Research Studies

Jiangxi Maternal and Child Health Hospital
2024-2025

Suzhou Institute of Systems Medicine
2020-2022

Chinese Academy of Medical Sciences & Peking Union Medical College
2020

National Taiwan University
2007

Genomics Research Center, Academia Sinica
2007

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a widespread outbreak of highly pathogenic disease 2019 (COVID-19). It is therefore important and timely to characterize interactions between the virus host cell at molecular level understand its pathogenesis. To gain insights, we performed high-throughput sequencing that generated time-series data simultaneously for bioinformatics analysis genomes transcriptomes implicated in SARS-CoV-2 infection. Our results showed...

10.3389/fmicb.2020.593857 article EN cc-by Frontiers in Microbiology 2020-11-25

QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of plus chemotherapy as first-line treatment in patients with advanced cervical cancer.

10.3802/jgo.2024.35.e77 article EN cc-by-nc Journal of Gynecologic Oncology 2024-01-01

5509 Background: The phase 3 COMPASSION-16 trial demonstrated statistically significant progression-free survival (PFS) and overall (OS) benefits with cadonilimab plus chemotherapy ± bevacizumab in patients persistent, recurrent, or metastatic cervical cancer (R/M CC). This analysis assessed efficacy several key clinical subgroups. Methods: R/M CC pts who had no prior systemic treatment were randomized 1:1 to receive (10 mg/kg) placebo Q3W platinum-based (15 mg/kg). dual primary endpoints...

10.1200/jco.2025.43.16_suppl.5509 article EN Journal of Clinical Oncology 2025-05-28

Abstract The genus Culicoides includes biting midges, some of which are vectors for viruses that cause diseases in humans and animals. Knowledge the roles viral ecology is inadequate. We collected ~300 000 samples mosquitoes 15 representative regions within Yunnan, China. Using as reference vectors, we designed a comparative virome strategy to study composition, diversity, hosts spatiotemporal distribution Culicoides. A map viromes Yunan province, China, was constructed. At same locations,...

10.1093/bib/bbaa323 article EN Briefings in Bioinformatics 2020-10-21

Jingmen tick virus (JMTV) is a novel tick-borne segmented RNA that closely related to un-segmental in evolution. It has been confirmed JMTV could be causative agent of human disease. In this study, total 3658 ticks were sampled from 7 provinces China and then divided into 545 pools according the location species. QRT-PCR nested PCR performed confirm presence JMTV. The results showed was identified 5 out with an average infection rate 1.4% (51/3658). Phylogenetic analysis indicated all...

10.1016/j.isci.2022.105007 article EN cc-by-nc-nd iScience 2022-08-25

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a widespread outbreak of highly pathogenic COVID-19. It is therefore important and timely to characterize interactions between the virus host cell at molecular level understand its disease pathogenesis. To gain insights, we performed high-throughput sequencing that generated time-series data simultaneously for bioinformatics analysis genomes transcriptomes implicated in SARS-CoV-2 infection. Our results showed...

10.1101/2020.04.30.071274 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2020-05-01
Coming Soon ...